Efalizumab Completed Phase 3 Trials for Psoriasis, Moderate to Severe Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00256139CLEAR Study: Clinical Experience Acquired With Raptiva Study
NCT00442650Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis